FinnCap reaffirmed their corporate rating on shares of Bioventix PLC (LON:BVXP) in a report published on Thursday morning. FinnCap currently has a GBX 1,750 ($22.72) price objective on the biotechnology company’s stock.

Bioventix PLC (LON BVXP) opened at 2195.00 on Thursday. The stock’s 50 day moving average is GBX 1,964.73 and its 200 day moving average is GBX 1,832.84. The company’s market cap is GBX 111.35 million. Bioventix PLC has a 12 month low of GBX 1,075.00 and a 12 month high of GBX 2,200.00.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at

About Bioventix PLC

Bioventix PLC is a United Kingdom-based biotechnology company. The principal activity of the Company is the development and supply of antibodies. The Company specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing.

Receive News & Stock Ratings for Bioventix PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventix PLC and related stocks with our FREE daily email newsletter.